Our findings offer insights into possible mechanisms through which obesity triggers AF and support NOX2 inhibition as a potential novel prophylactic or adjunctive therapy for patients with obesity-mediated AF. Here, CYBB is linked to obesity due to melanocortin 4 receptor deficiency.